The effect of combined androgen ablation on the expression of alpha 1A-adrenergic receptor in the human prostate

Elie A. Benaim, Jose A. Karam, M. Hossein Soboorian, Claus Roehrborn, John D. McConnell, Victor Lin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

BACKGROUND. This study was designed to determine whether androgen ablation (AA) affects expression of alpha1A-adrenergic receptors (AR) in the human prostate. METHODS. Concentrations of alpha1A-AR mRNA were determined in benign prostatic tissue from patients undergoing surgery after a 3-month course of combined androgen ablation (CAD) therapy with leuprolide and flutamide, and a matched group of untreated patients with clinical BPH. RESULTS. Mean concentration of alpha1A-AR in the AA group was 0.53 ± 0.53 SD (range 0.026-1.55) attomol/mg. Control mean was 0.29 ± 0.22 SD (range 0.02-0.69; P = 0.3, two tailed t-test). Tissue composition did not statistically differ between the two groups. Expression of alpha1A-AR correlated with concentration of smooth muscle myosin heavy chain (SMMHC) (r = 0.84, P = 0.001). No significant differences were observed after adjusting for SMMHC content. CONCLUSIONS. A 3-month course of CAD does not appear to have a significant effect on alpha1A-AR mRNA expression in the human prostate.

Original languageEnglish (US)
Pages (from-to)310-316
Number of pages7
JournalProstate
Volume60
Issue number4
DOIs
StatePublished - Sep 1 2004

Fingerprint

Adrenergic alpha-1 Receptors
Adrenergic Receptors
Androgens
Prostate
Smooth Muscle Myosins
Myosin Heavy Chains
Leuprolide
Flutamide
Messenger RNA
Research Design

Keywords

  • Alpha blocker therapy
  • Androgen ablation
  • BPH
  • MRNA expression
  • RT-PCR

ASJC Scopus subject areas

  • Urology

Cite this

The effect of combined androgen ablation on the expression of alpha 1A-adrenergic receptor in the human prostate. / Benaim, Elie A.; Karam, Jose A.; Soboorian, M. Hossein; Roehrborn, Claus; McConnell, John D.; Lin, Victor.

In: Prostate, Vol. 60, No. 4, 01.09.2004, p. 310-316.

Research output: Contribution to journalArticle

Benaim, Elie A. ; Karam, Jose A. ; Soboorian, M. Hossein ; Roehrborn, Claus ; McConnell, John D. ; Lin, Victor. / The effect of combined androgen ablation on the expression of alpha 1A-adrenergic receptor in the human prostate. In: Prostate. 2004 ; Vol. 60, No. 4. pp. 310-316.
@article{a4310c3348294f0f9931eb7f9e07eb4a,
title = "The effect of combined androgen ablation on the expression of alpha 1A-adrenergic receptor in the human prostate",
abstract = "BACKGROUND. This study was designed to determine whether androgen ablation (AA) affects expression of alpha1A-adrenergic receptors (AR) in the human prostate. METHODS. Concentrations of alpha1A-AR mRNA were determined in benign prostatic tissue from patients undergoing surgery after a 3-month course of combined androgen ablation (CAD) therapy with leuprolide and flutamide, and a matched group of untreated patients with clinical BPH. RESULTS. Mean concentration of alpha1A-AR in the AA group was 0.53 ± 0.53 SD (range 0.026-1.55) attomol/mg. Control mean was 0.29 ± 0.22 SD (range 0.02-0.69; P = 0.3, two tailed t-test). Tissue composition did not statistically differ between the two groups. Expression of alpha1A-AR correlated with concentration of smooth muscle myosin heavy chain (SMMHC) (r = 0.84, P = 0.001). No significant differences were observed after adjusting for SMMHC content. CONCLUSIONS. A 3-month course of CAD does not appear to have a significant effect on alpha1A-AR mRNA expression in the human prostate.",
keywords = "Alpha blocker therapy, Androgen ablation, BPH, MRNA expression, RT-PCR",
author = "Benaim, {Elie A.} and Karam, {Jose A.} and Soboorian, {M. Hossein} and Claus Roehrborn and McConnell, {John D.} and Victor Lin",
year = "2004",
month = "9",
day = "1",
doi = "10.1002/pros.20070",
language = "English (US)",
volume = "60",
pages = "310--316",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - The effect of combined androgen ablation on the expression of alpha 1A-adrenergic receptor in the human prostate

AU - Benaim, Elie A.

AU - Karam, Jose A.

AU - Soboorian, M. Hossein

AU - Roehrborn, Claus

AU - McConnell, John D.

AU - Lin, Victor

PY - 2004/9/1

Y1 - 2004/9/1

N2 - BACKGROUND. This study was designed to determine whether androgen ablation (AA) affects expression of alpha1A-adrenergic receptors (AR) in the human prostate. METHODS. Concentrations of alpha1A-AR mRNA were determined in benign prostatic tissue from patients undergoing surgery after a 3-month course of combined androgen ablation (CAD) therapy with leuprolide and flutamide, and a matched group of untreated patients with clinical BPH. RESULTS. Mean concentration of alpha1A-AR in the AA group was 0.53 ± 0.53 SD (range 0.026-1.55) attomol/mg. Control mean was 0.29 ± 0.22 SD (range 0.02-0.69; P = 0.3, two tailed t-test). Tissue composition did not statistically differ between the two groups. Expression of alpha1A-AR correlated with concentration of smooth muscle myosin heavy chain (SMMHC) (r = 0.84, P = 0.001). No significant differences were observed after adjusting for SMMHC content. CONCLUSIONS. A 3-month course of CAD does not appear to have a significant effect on alpha1A-AR mRNA expression in the human prostate.

AB - BACKGROUND. This study was designed to determine whether androgen ablation (AA) affects expression of alpha1A-adrenergic receptors (AR) in the human prostate. METHODS. Concentrations of alpha1A-AR mRNA were determined in benign prostatic tissue from patients undergoing surgery after a 3-month course of combined androgen ablation (CAD) therapy with leuprolide and flutamide, and a matched group of untreated patients with clinical BPH. RESULTS. Mean concentration of alpha1A-AR in the AA group was 0.53 ± 0.53 SD (range 0.026-1.55) attomol/mg. Control mean was 0.29 ± 0.22 SD (range 0.02-0.69; P = 0.3, two tailed t-test). Tissue composition did not statistically differ between the two groups. Expression of alpha1A-AR correlated with concentration of smooth muscle myosin heavy chain (SMMHC) (r = 0.84, P = 0.001). No significant differences were observed after adjusting for SMMHC content. CONCLUSIONS. A 3-month course of CAD does not appear to have a significant effect on alpha1A-AR mRNA expression in the human prostate.

KW - Alpha blocker therapy

KW - Androgen ablation

KW - BPH

KW - MRNA expression

KW - RT-PCR

UR - http://www.scopus.com/inward/record.url?scp=3943084846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3943084846&partnerID=8YFLogxK

U2 - 10.1002/pros.20070

DO - 10.1002/pros.20070

M3 - Article

VL - 60

SP - 310

EP - 316

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 4

ER -